Literature DB >> 11268953

Therapy of HCC-radiofrequency ablation.

L Buscarini1, E Buscarini.   

Abstract

Radiofrequency interstitial hyperthermia has been used for percutaneous ablation of hepatocellular carcinoma, under ultrasound guidance in local anesthesia. Conventional needle electrodes require a mean number of 3 sessions to treat tumors of diameter < or = 3 cm. Tumors up to 3.5 cm in diameter can be treated in 1 or 2 sessions by expandable needle electrodes. With both methods in all treated cases, ablation of tumors was obtained. In a group of patients with long follow-up, survival rate at 5 years was 40%. In a mean follow-up of 23 months 41% of patients had recurrences (local recurrences in 5%; new lesions in 36%), which often could be retreated by a new course of radiofrequency application. In recent experience large hepatocellular carcinomas (up to 6.8 cm in diameter) were treated by a combination of segmental transcatheter arterial embolization followed by radiofrequency application. In this way most tumors were ablated in one session of radiofrequency therapy. No fatal complications were observed. Major complications were: strong pain due to capsular necrosis in one patient; hemotorax in one case; a fluid collection in the site of ablated tumor in one patient treated by combination of transcatheter arterial embolization and radiofrequency application.

Entities:  

Mesh:

Year:  2001        PMID: 11268953

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  6 in total

Review 1.  Radiofrequency thermal ablation of liver tumors.

Authors:  Elisabetta Buscarini; Agostino Savoia; Gianfranco Brambilla; Fernanda Menozzi; Luigi Reduzzi; Deike Strobel; Johannes Hänsler; Luigi Buscarini; Luigi Gaiti; Alessandro Zambelli
Journal:  Eur Radiol       Date:  2005-03-08       Impact factor: 5.315

2.  Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma.

Authors:  Koichi Obara; Nobuyuki Matsumoto; Masaru Okamoto; Minoru Kobayashi; Hiroki Ikeda; Hideaki Takahashi; Yoshiki Katakura; Kotaro Matsunaga; Toshiya Ishii; Chiaki Okuse; Michihiro Suzuki; Fumio Itoh
Journal:  Hepatol Int       Date:  2008-01-29       Impact factor: 6.047

Review 3.  Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma.

Authors:  Loukia S Poulou; Evanthia Botsa; Ioanna Thanou; Panayiotis D Ziakas; Loukas Thanos
Journal:  World J Hepatol       Date:  2015-05-18

4.  Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study.

Authors:  Guan-Tarn Huang; Po-Huang Lee; Yuk-Ming Tsang; Ming-Yang Lai; Pei-Ming Yang; Rey-Heng Hu; Pei-Jer Chen; Jia-Horng Kao; Jin-Chuan Sheu; Cha-Ze Lee; Ding-Shinn Chen
Journal:  Ann Surg       Date:  2005-07       Impact factor: 12.969

5.  Local recurrence is an important prognostic factor of hepatocellular carcinoma.

Authors:  Eiichirou Arimura; Kazuhiro Kotoh; Makoto Nakamuta; Shusuke Morizono; Munechika Enjoji; Hajime Nawata
Journal:  World J Gastroenterol       Date:  2005-09-28       Impact factor: 5.742

6.  Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients.

Authors:  Steven A Curley; Paolo Marra; Karen Beaty; Lee M Ellis; J Nicolas Vauthey; Eddie K Abdalla; Courtney Scaife; Chan Raut; Robert Wolff; Haesun Choi; Evelyne Loyer; Paolo Vallone; Francesco Fiore; Fabrizio Scordino; Vincenzo De Rosa; Raffaele Orlando; Sandro Pignata; Bruno Daniele; Francesco Izzo
Journal:  Ann Surg       Date:  2004-04       Impact factor: 12.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.